Single-Chain Fusion Proteins for Nociceptive Afferent Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for constructing non-cytotoxic fusion proteins, such as those targeting nociceptive sensory afferents, face challenges in achieving optimal binding affinity and therapeutic efficacy due to imprecise chemical conjugation techniques and reduced binding ability of recombinant fusion proteins with C-terminal targeting moieties.
Innovation Solution
A single-chain polypeptide fusion protein design is introduced, featuring a non-cytotoxic protease, a targeting moiety capable of binding to nociceptive sensory afferents, a protease cleavage site between the protease and targeting moiety, and a translocation domain for intracellular delivery, optimizing binding and therapeutic effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If chemical conjugation techniques are used to construct non-cytotoxic fusion proteins, then the proteins can be assembled with different components, but the binding affinity and therapeutic efficacy are reduced due to imprecise conjugation
Solution Approach 1:
The patent replaces chemical conjugation methods with a biological proteolytic cleavage system. A protease cleavage site is incorporated into the fusion protein sequence, allowing a protease to specifically cleave the precursor fusion protein at the designated site. This biological system provides precise, site-specific processing that chemical methods cannot achieve, resulting in proper protein assembly with optimal binding affinity and therapeutic efficacy.
2Ease of manufacture
If recombinant fusion proteins with C-terminal targeting moieties are constructed, then the proteins can be produced through recombinant technology, but the binding ability is reduced
Solution Approach 1:
The fusion protein is segmented into distinct functional domains: an N-terminal protease domain, a central protease cleavage site, a translocation domain, and a C-terminal targeting moiety. This segmentation allows each component to perform its specific function optimally. The protease cleavage site enables precise processing that releases the targeting moiety in its active conformation, ensuring high binding ability while maintaining the advantages of recombinant production.
3Ease of operation
If conventional analgesic dosages are used, then standard therapeutic protocols can be followed, but higher dosages are required compared to the fusion proteins
Solution Approach 1:
The invention changes the fundamental parameters of the therapeutic agent by using a non-cytotoxic protease fusion protein instead of conventional analgesics. This parameter change results in dramatically improved potency, requiring much lower dosages (nanogram to picogram range) compared to conventional analgesics (milligram range). The protease mechanism of action, which cleaves specific neural proteins to block pain signaling, provides superior therapeutic effect at extremely low concentrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion proteins demonstrate enhanced binding efficacy and therapeutic potency, achieving significant analgesic effects at lower dosages compared to conventional analgesics, with improved specificity and reduced binding affinity issues.
Implementation Method 1
a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent
Implementation Method 2
a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the targeting moiety
Implementation Method 3
a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent
Data Source
AI summary
A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.